• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用单价疫苗或其三价组合疫苗接种的犊牛的体液免疫反应以及这些疫苗与埃塞俄比亚选定的流行口蹄疫病毒的匹配情况。

Humoral Immune Response in Calves Vaccinated with Monovalent Vaccines or a Trivalent Combination Thereof and Matching of These Vaccines to the Selected Circulating Foot-and-Mouth Disease Viruses in Ethiopia.

作者信息

Woldemariyam Fanos Tadesse, Negessu Demessa, Bilata Tsion, Muluneh Ayelech, Gebreweld Dereje Shegu, Ebisa Ibsa Teshome, Paeshuyse Jan

机构信息

Laboratory of Host-Pathogen Interaction in Livestock, Division of Animal and Human Health Engineering, Department of Biosystems, KU Leuven, 3000 Leuven, Belgium.

College of Veterinary Medicine, Addis Ababa University, Bishoftu P.O. Box 34, Ethiopia.

出版信息

Vaccines (Basel). 2023 Aug 10;11(8):1352. doi: 10.3390/vaccines11081352.

DOI:10.3390/vaccines11081352
PMID:37631920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10457929/
Abstract

Foot-and-mouth disease (FMD) is an endemic, highly contagious, and devastating disease of livestock production in Ethiopia. Control of this disease relies mainly on prophylactic vaccination by willing farmers without a countrywide vaccination program. The objectives of this study were to quantify the humoral immune response and evaluation of the serological relationship of the vaccine strain used with representative field strain isolates. This was performed by primo vaccination of 6-9-month-old Holstein Friesian calves (35 treatment and 4 control calves) on day one and booster vaccination on day 28. Calves were vaccinated using the locally available National Veterinary Institute (NVI), Bishoftu, Ethiopia, inactivated aluminum hydroxide adjuvant monovalent (either O, A, SAT-2 alone) or trivalent (combination of A, O, SAT-2) vaccine (A/ETH/6/2000 (G-VII, O/ETH/38/2005(EA-3) and SAT-2/ETH/64/2009(XIII)). A 2 mL or 4 mL dose was used to vaccinate all calves except the animals that served as a control. In the case of the trivalent vaccine, a 4 mL dose was used to vaccinate calves. The serum was collected at 7, 14, 21, 28, and 56 days post-vaccination (d.p.v.). The humoral immune response was quantified by the solid-phase competitive enzyme-linked immunosorbent assay (SPC ELISA) and the virus-neutralization test (VNT). The serological relationship of heterologous and homologous viruses was also evaluated by adjuvant vaccine matching tests. The r1-value was determined using serum collected 21 d.p.v. An increase in immune response was observed from 7 d.p.v. to 28 d.p.v. in calves who received a 4 mL dose containing a 10 antigen load of 100 tissue culture infective dose (100TCID50) virus titer in the formulation. Upon receiving a booster dose on day 28, the humoral immune response was checked on the 56th day post-initial vaccination. Amounts of 54%, 72%, 79%, and 72% of inhibition for A, O, SAT-2, and trivalent vaccine in the three serotypes SPCE, respectively, was measured. Here, it was found that the immune response of calves increased from day 7 to 56, as evidenced by SPCE analysis. Likewise, an increase in antibody titer measured by a one-dimensional virus neutralization assay was also in line with SPCE analysis. This indicates that the vaccine is capable of inducing a neutralizing antibody that confers a protective immune response in 70%, 62%, and 100% heterologous field strains of A, O, and SAT-2 isolates, respectively, and has an average antigenic relationship of >0.3 with a standard deviation of +0.05 (N = 3) to the vaccine strains A/ETH/6/2000, O/ETH/38/2005 and SAT-2/ETH/64/2009, respectively, when using the one-dimensional virus neutralization test. The contribution and importance of this study is a confirmation of the vaccine and the field strain serological relationship for serotype SAT-2 strain and further research/change of vaccination strategy/ improvement in the currently used vaccine to cover a wide range of prevailing genotypes/lineages and induction of sound immune response after vaccination for serotype A and O strain. This study suggests that the trivalent vaccine produced by the National Veterinary Institute containing viral isolates from serotype O, A, and SAT-2 has a good serological relationship with the majority of circulating field strains in Ethiopia.

摘要

口蹄疫(FMD)是埃塞俄比亚家畜生产中一种地方性流行、高度传染性且具有毁灭性的疾病。对这种疾病的控制主要依赖于自愿接种疫苗的农民进行预防性接种,而没有全国性的疫苗接种计划。本研究的目的是量化体液免疫反应,并评估所用疫苗株与代表性田间毒株分离株之间的血清学关系。这是通过在第1天对6至9月龄的荷斯坦弗里生犊牛(35头治疗组犊牛和4头对照组犊牛)进行初次接种,并在第28天进行加强接种来完成的。使用埃塞俄比亚比绍夫图当地可获得的国家兽医研究所(NVI)的灭活氢氧化铝佐剂单价(仅O、A、SAT - 2)或三价(A、O、SAT - 2组合)疫苗(A/ETH/6/2000(G - VII)、O/ETH/38/2005(EA - 3)和SAT - 2/ETH/64/2009(XIII))对犊牛进行接种。除作为对照的动物外,所有犊牛均使用2 mL或4 mL剂量进行接种。对于三价疫苗,使用4 mL剂量对犊牛进行接种。在接种后第7、14、21、28和56天采集血清。通过固相竞争酶联免疫吸附测定(SPC ELISA)和病毒中和试验(VNT)量化体液免疫反应,并通过佐剂疫苗匹配试验评估异源和同源病毒的血清学关系。使用接种后第21天采集的血清测定r1值。在接种含100组织培养感染剂量(100TCID50)病毒滴度的10抗原负荷的4 mL剂量的犊牛中,观察到从接种后第7天到第28天免疫反应增加。在第28天接受加强剂量后,在初次接种后的第56天检查体液免疫反应。在三种血清型的SPCE中,分别测得A、O、SAT - 2和三价疫苗的抑制率为54%(原文此处可能有误,按逻辑推测为54%左右,下同)、72%、79%和72%。在此,通过SPCE分析发现犊牛的免疫反应从第7天到第56天增加。同样,通过一维病毒中和试验测得抗体滴度的增加也与SPCE分析一致。这表明该疫苗能够分别在70%、62%和100%的A、O和SAT - 2分离株的异源田间毒株中诱导产生具有保护性免疫反应的中和抗体,并且当使用一维病毒中和试验时,与疫苗株A/ETH/6/2000、O/ETH/38/2005和SAT - 2/ETH/64/2009的平均抗原关系>0.3,标准差为±0.05(N = 3)。本研究的贡献和重要性在于确认了疫苗与SAT - 2血清型毒株的田间毒株血清学关系,并进一步研究/改变疫苗接种策略/改进目前使用的疫苗,以涵盖广泛流行的基因型/谱系,并在接种后对A和O血清型毒株诱导良好的免疫反应。本研究表明,国家兽医研究所生产的含血清型O、A和SAT - 2病毒分离株的三价疫苗与埃塞俄比亚大多数流行的田间毒株具有良好的血清学关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/f5d209a724ef/vaccines-11-01352-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/c6200894e67a/vaccines-11-01352-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/ef39ab97419b/vaccines-11-01352-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/70756319d9b7/vaccines-11-01352-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/f5d209a724ef/vaccines-11-01352-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/c6200894e67a/vaccines-11-01352-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/ef39ab97419b/vaccines-11-01352-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/70756319d9b7/vaccines-11-01352-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bce/10457929/f5d209a724ef/vaccines-11-01352-g004.jpg

相似文献

1
Humoral Immune Response in Calves Vaccinated with Monovalent Vaccines or a Trivalent Combination Thereof and Matching of These Vaccines to the Selected Circulating Foot-and-Mouth Disease Viruses in Ethiopia.用单价疫苗或其三价组合疫苗接种的犊牛的体液免疫反应以及这些疫苗与埃塞俄比亚选定的流行口蹄疫病毒的匹配情况。
Vaccines (Basel). 2023 Aug 10;11(8):1352. doi: 10.3390/vaccines11081352.
2
Analysis of the immunological response elicited by a polyvalent foot and mouth disease vaccine and its compatibility with a diva test in Jimma Town, Ethiopia.分析多价口蹄疫疫苗引起的免疫反应及其与埃塞俄比亚 Jimma 镇 DIVA 检测的兼容性。
Virol J. 2024 Oct 7;21(1):250. doi: 10.1186/s12985-024-02485-w.
3
Vaccine matching and antigenic variability of foot-and-mouth disease virus serotypes O and A from 2018 Ethiopian isolates.2018 年埃塞俄比亚分离株的口蹄疫病毒血清型 O 和 A 的疫苗匹配和抗原变异性。
Int Microbiol. 2022 Jan;25(1):47-59. doi: 10.1007/s10123-021-00178-w. Epub 2021 Jul 5.
4
Foot and Mouth Disease Vaccine Matching and Post-Vaccination Assessment in Abu Dhabi, United Arab Emirates.阿拉伯联合酋长国阿布扎比的口蹄疫疫苗匹配与疫苗接种后评估
Vet Sci. 2024 Jun 14;11(6):272. doi: 10.3390/vetsci11060272.
5
A vaccine-matching assessment of different genetic variants of serotype O foot-and-mouth disease virus isolated in Ethiopia between 2011 and 2014.对 2011 年至 2014 年期间在埃塞俄比亚分离的 O 型口蹄疫病毒不同遗传变异株的疫苗匹配评估。
Arch Virol. 2020 Aug;165(8):1749-1757. doi: 10.1007/s00705-020-04662-y. Epub 2020 May 20.
6
Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle.表达口蹄疫病毒印度疫苗株衣壳蛋白的重组人腺病毒5型在牛体内引发有效的抗体反应。
Vet Microbiol. 2017 May;203:196-201. doi: 10.1016/j.vetmic.2017.03.019. Epub 2017 Mar 18.
7
Challenges for Serology-Based Characterization of Foot-and-Mouth Disease Outbreaks in Endemic Areas; Identification of Two Separate Lineages of Serotype O FMDV in Uganda in 2011.流行地区口蹄疫疫情基于血清学特征分析面临的挑战;2011年乌干达O型口蹄疫病毒两个不同谱系的鉴定
Transbound Emerg Dis. 2015 Oct;62(5):522-34. doi: 10.1111/tbed.12170. Epub 2013 Oct 11.
8
The effects of simultaneous foot-and-mouth disease and Escherichia coli vaccination on the immunity of pregnant cows and their calves.口蹄疫和大肠杆菌联合疫苗接种对怀孕母牛及其犊牛免疫力的影响。
Prev Vet Med. 2022 Jul;204:105645. doi: 10.1016/j.prevetmed.2022.105645. Epub 2022 Apr 6.
9
Assessment of the potency and effectiveness of a heptavalent oil-adjuvanted (ISA 206) foot-and-mouth disease vaccine in Egypt.评估一种七价油佐剂(ISA 206)口蹄疫疫苗在埃及的效力和效果。
Arch Virol. 2023 Jan 12;168(2):62. doi: 10.1007/s00705-022-05624-2.
10
Immune Modulatory Potential of Anti-idiotype Antibodies as a Surrogate of Foot-and-Mouth Disease Virus Antigen.抗独特型抗体的免疫调节潜力可作为口蹄疫病毒抗原的替代物。
mSphere. 2018 Oct 17;3(5):e00522-18. doi: 10.1128/mSphere.00522-18.

本文引用的文献

1
The history of foot-and-mouth disease virus serotype C: the first known extinct serotype?口蹄疫病毒C型的历史:首个已知的灭绝血清型?
Virus Evol. 2021 Mar 19;7(1):veab009. doi: 10.1093/ve/veab009. eCollection 2021 Jan.
2
Vaccine matching and antigenic variability of foot-and-mouth disease virus serotypes O and A from 2018 Ethiopian isolates.2018 年埃塞俄比亚分离株的口蹄疫病毒血清型 O 和 A 的疫苗匹配和抗原变异性。
Int Microbiol. 2022 Jan;25(1):47-59. doi: 10.1007/s10123-021-00178-w. Epub 2021 Jul 5.
3
Improved immune responses and safety of foot-and-mouth disease vaccine containing immunostimulating components in pigs.
含免疫刺激成分的口蹄疫疫苗在猪体内的免疫反应及安全性得到改善。
J Vet Sci. 2020 Sep;21(5):e74. doi: 10.4142/jvs.2020.21.e74.
4
Molecular characterization of foot-and-mouth disease viruses circulating in Ethiopia between 2008 and 2019.2008 年至 2019 年期间在埃塞俄比亚流行的口蹄疫病毒的分子特征。
Transbound Emerg Dis. 2020 Nov;67(6):2983-2992. doi: 10.1111/tbed.13675. Epub 2020 Jul 1.
5
A vaccine-matching assessment of different genetic variants of serotype O foot-and-mouth disease virus isolated in Ethiopia between 2011 and 2014.对 2011 年至 2014 年期间在埃塞俄比亚分离的 O 型口蹄疫病毒不同遗传变异株的疫苗匹配评估。
Arch Virol. 2020 Aug;165(8):1749-1757. doi: 10.1007/s00705-020-04662-y. Epub 2020 May 20.
6
Towards improvements in foot-and-mouth disease vaccine performance.致力于提高口蹄疫疫苗的性能。
Acta Vet Scand. 2020 May 20;62(1):20. doi: 10.1186/s13028-020-00519-1.
7
Molecular characterization of foot-and-mouth disease viruses collected from Northern and Central Ethiopia during the 2018 outbreak.2018年疫情期间从埃塞俄比亚北部和中部采集的口蹄疫病毒的分子特征分析。
Vet World. 2020 Mar;13(3):542-548. doi: 10.14202/vetworld.2020.542-548. Epub 2020 Mar 24.
8
Selection of vaccine strains for serotype O foot-and-mouth disease viruses (2007-2012) circulating in Southeast Asia, East Asia and Far East.东南亚、东亚和远东地区流行的 O 型口蹄疫病毒(2007-2012 年)疫苗株的选择。
Vaccine. 2017 Dec 18;35(51):7147-7153. doi: 10.1016/j.vaccine.2017.10.099. Epub 2017 Nov 20.
9
Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain.东非口蹄疫病毒血清型 O 的遗传和抗原特征分析,以选择合适的疫苗株。
Vaccine. 2017 Dec 14;35(49 Pt B):6842-6849. doi: 10.1016/j.vaccine.2017.10.040.
10
Genetic and antigenic analysis of foot-and-mouth disease virus serotype O responsible for outbreaks in India during 2013.2013年在印度引发疫情的口蹄疫病毒O型的基因和抗原分析。
Infect Genet Evol. 2015 Mar;30:59-64. doi: 10.1016/j.meegid.2014.12.009. Epub 2014 Dec 13.